Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Randomized Trial of Low versus Moderate Exposure Busulfan for Infants with Severe Combined Immunodeficiency (SCID) Receiving TCRaB;+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC) PIDTC CSIDE Protocol (Conditioning SCID Infants Diagnosed Early) PBMTC NMD 1801

Disease Sites:

Not Available

Staging:

Phase II

Age Group:

Children

Therapies:

Not Available

Drugs:

Not Available

Principal Investigator(s):

Connelly, James

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

10-22-2018

Trial Type:

Treatment

Protocol ID:

VICCNCPED18122

National Clinical Trial ID:

NCT03619551

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available